Skip to main content
Clinical Trials/NCT02407691
NCT02407691
Completed
Not Applicable

Collaborative Care for the Detection and Management of Depression Among Adults Receiving Antiretroviral Therapy in South Africa: a Pragmatic Cluster Randomized Controlled Trial

University of Cape Town2 sites in 1 country2,002 target enrollmentApril 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
HIV/AIDS
Sponsor
University of Cape Town
Enrollment
2002
Locations
2
Primary Endpoint
Viral load suppression
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

With increasing access to antiretroviral therapy (ART) in South Africa, HIV has transitioned from a terminal illness to a long-term condition. It is likely to be accompanied by higher levels of disability and other chronic non-communicable diseases, resulting from the HIV itself, as well as adverse effects of medication. This requires an expansion of the purview of HIV care beyond direct HIV clinical care to also include a more comprehensive and integrated package of treatment and care for physical and mental conditions and their consequences. COBALT is a pragmatic cluster randomized controlled trial (RCT) in public sector primary care clinics in the North West Province of SA. It will assess mental health and HIV outcomes for depressed adults receiving ART by measuring the real-world effectiveness of a facility-based stepped care intervention combining depression case detection by non-physician clinicians with group counselling intervention delivered by lay-health workers.

Registry
clinicaltrials.gov
Start Date
April 2015
End Date
January 2018
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Babalwa Zani

www.knowledgetranslation.co.za

University of Cape Town

Eligibility Criteria

Inclusion Criteria

  • 40 nurse-led primary care clinics providing ART in the Dr Kenneth Kaunda and Bojonala districts of the North West Province, South Africa
  • Age ≥ 18 years and
  • Receiving ART at the time of enrollment and
  • Depressive symptoms, as indicated by a total score of 9 or more on the PHQ-9 and
  • Planning to reside in the area for the next year and
  • Capable of actively engaging in an interviewer-administered questionnaire at the time of recruitment, six and twelve months later and
  • Written consent to participate in the study

Exclusion Criteria

  • Clinics which participate in the formative research and piloting of the intervention
  • Inability to meet the above inclusion criteria

Outcomes

Primary Outcomes

Viral load suppression

Time Frame: 12 months

viral load value of \<1000 RNA copies/ml

Patient Health Questionnaire 9 (PHQ-9) response

Time Frame: 6 months

At least 50% improvement in PHQ-9 score compared with baseline

Secondary Outcomes

  • PHQ-9 Response at 12 months(12 months)
  • Depression Remission at 12 months(12 months)
  • Mean PHQ-9 score at 6 and 12 months(6 and 12 months)
  • Antiretroviral therapy programme retention(12 months)
  • Viral load suppression at 12 months(12 months)
  • Virological failure(12 months)
  • Appropriate maintenance on enrollment ART regimen OR ART regimen switched to second-line(12 months)
  • ART adherence(12 months)
  • Change in viral load values over time(12 months)
  • Depression severity (categorised as mild, moderate, moderately severe or severe depression at 6 and 12 months)(6 and 12 months)
  • Antidepressant treatment initiated or intensified(12 months)
  • Counselling for depression by a clinic-based counsellor(12 months)
  • Referral to specialist mental health worker/service(12 months)
  • Hospital admissions(12 months)
  • Mortality(12 months)
  • Stress(12 months)
  • Risk factors for cardiovascular diseases(12 months)
  • Detection and treatment of other chronic diseases(12 months)
  • Stigma(12 months)
  • Provision of integrated care from patient perspective(12 months)

Study Sites (2)

Loading locations...

Similar Trials